During the 19th Annual Biomarkers Congress (29 February - 1 March 2024, London, UK) our experts will be ready to discuss your challenges in biomarker assay development, validation and biomarker studies.

The use of biomarkers to quicken timelines and ensure clinical success in drug development will be a key topic discussed at the 19th Annual Biomarkers Congress. As the pharmaceutical industry focuses on achieving increasingly more efficient and successful drug development through informed decision making, meet our experts at Booth 1 during the conference to discuss how Intertek can support your biomarker assay development, validation and biomarker studies. Contact us to arrange a meeting during the event.

Our Biomarker and Bioanalysis Expertise
Our biomarker services provide fit-for-purpose validations in support of exploratory biomarkers based on your product requirements and full validation for confirmatory biomarkers where clinical decisions are being made to understand the drug’s efficacy and safety profile. Intertek utilises a diverse array of analytical platforms to support biomarker analysis including ELISA, flow cytometry, cell-based assays and ECL multiplex platforms. 

We also provide bioanalytical pharmacokinetic and immunogenicity analysis for pre-clinical and clinical studies. Our GMP and CMC support programs include biologic product characterization packages, method development and validation, impurities analysis, stability, batch release and cell based potency testing. We apply our experience and depth of industry knowledge to help you to navigate the challenges of new product development, scale-up, manufacturing, bioanalysis and market release to meet regulatory expectations

 

More about the 19th Annual Biomarkers Congress

Join over 500 leading pharma, biotech, & academic delegates all engaged in diverse therapeutic areas and stages of drug development, for 20 hours of presentations, discussions & interactive content on the latest developments in biomarker applications, methods, best practice and regulatory considerations.